222 related articles for article (PubMed ID: 30802305)
1. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.
Vollenbrock SE; Voncken FEM; van Dieren JM; Lambregts DMJ; Maas M; Meijer GJ; Goense L; Mook S; Hartemink KJ; Snaebjornsson P; Ter Beek LC; Verheij M; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Br J Surg; 2019 Apr; 106(5):596-605. PubMed ID: 30802305
[TBL] [Abstract][Full Text] [Related]
2. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
[TBL] [Abstract][Full Text] [Related]
3. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
[TBL] [Abstract][Full Text] [Related]
4. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.
Vollenbrock SE; van Dieren JM; Voncken FEM; van Turenhout ST; Kodach LL; Hartemink KJ; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur Radiol; 2020 May; 30(5):2425-2434. PubMed ID: 31965258
[TBL] [Abstract][Full Text] [Related]
5. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
6. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
[TBL] [Abstract][Full Text] [Related]
8. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
[TBL] [Abstract][Full Text] [Related]
9. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.
Heethuis SE; Goense L; van Rossum PSN; Borggreve AS; Mook S; Voncken FEM; Bartels-Rutten A; Aleman BMP; van Hillegersberg R; Ruurda JP; Meijer GJ; Lagendijk JJW; van Lier ALHMW
Acta Oncol; 2018 Sep; 57(9):1201-1208. PubMed ID: 29781342
[TBL] [Abstract][Full Text] [Related]
10. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
11. MRI and Diffusion-weighted MRI Volumetry for Identification of Complete Tumor Responders After Preoperative Chemoradiotherapy in Patients With Rectal Cancer: A Bi-institutional Validation Study.
Lambregts DM; Rao SX; Sassen S; Martens MH; Heijnen LA; Buijsen J; Sosef M; Beets GL; Vliegen RA; Beets-Tan RG
Ann Surg; 2015 Dec; 262(6):1034-9. PubMed ID: 25211270
[TBL] [Abstract][Full Text] [Related]
12. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
13. Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.
Chao YK; Chang Y; Yeh CJ; Chang HK; Tseng CK; Chuang WY
Br J Surg; 2016 Dec; 103(13):1874-1879. PubMed ID: 27620361
[TBL] [Abstract][Full Text] [Related]
14. Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?
Heneghan HM; Donohoe C; Elliot J; Ahmed Z; Malik V; Ravi N; Reynolds JV
Ann Surg; 2016 Nov; 264(5):831-838. PubMed ID: 27741010
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Lambregts DM; Vandecaveye V; Barbaro B; Bakers FC; Lambrecht M; Maas M; Haustermans K; Valentini V; Beets GL; Beets-Tan RG
Ann Surg Oncol; 2011 Aug; 18(8):2224-31. PubMed ID: 21347783
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study.
Bates DDB; Golia Pernicka JS; Fuqua JL; Paroder V; Petkovska I; Zheng J; Capanu M; Schilsky J; Gollub MJ
Abdom Radiol (NY); 2020 Feb; 45(2):293-300. PubMed ID: 31690966
[TBL] [Abstract][Full Text] [Related]
17. Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer.
Intven M; Monninkhof EM; Reerink O; Philippens ME
Acta Oncol; 2015 Nov; 54(10):1729-36. PubMed ID: 25914930
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
De Felice F; Magnante AL; Musio D; Ciolina M; De Cecco CN; Rengo M; Laghi A; Tombolini V
Eur J Surg Oncol; 2017 Jul; 43(7):1324-1329. PubMed ID: 28363512
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
20. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
